New studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating encouraging effects in treating obesity and related second-type diabetes. Preclinical data suggest a unique action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/